CA2684404A1 — Novel piperazine salts as d3/d2 antagonists
Assigned to Richter Gedeon Nyrt · Expires 2008-11-20 · 17y expired
What this patent protects
The present invention relates to novel monohydrochloride, dihydrochloride , monohydrobromide, maleate and methanesulphonate salts of trans 4-{2-[4-(2, 3-dichlorophenyl)-piperazine-1-yl]-ethyl}-N,N-dimethylcarbamoyl-cyclohexylam ine and/or their hydrates and/or solvates. Moreover,…
USPTO Abstract
The present invention relates to novel monohydrochloride, dihydrochloride , monohydrobromide, maleate and methanesulphonate salts of trans 4-{2-[4-(2, 3-dichlorophenyl)-piperazine-1-yl]-ethyl}-N,N-dimethylcarbamoyl-cyclohexylam ine and/or their hydrates and/or solvates. Moreover, the invention relates t o the process for preparing the salts and their hydrates and/or solvates, to their use in the treatment and/or prevention of conditions which require mo dulation of dopamine receptor and to pharmaceutical compositions containing them.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.